Euratom: Where Are We Now?
Hamid Yunis, partner and head of healthcare at the London office of international law firm, McDermott Will & Emery, discusses the potential negative impact of Brexit and the UK leaving…
Address: Richmond House, 79 Whitehall, London SW1A 2NS,United Kingdom
Tel: +44 (0)20 7210 4850
Web: http://www.dh.gov.uk/health/about-us/
The Department of Health’s purpose is to improve England’s health and well-being and in doing so achieve better health, better care, and better value for all.
The vision for health and social care is focused around five key priorities:
A patient-led NHS
Delivering better health outcomes
A more autonomous and accountable system
Improved public health
Reforming long-term and social care
The work of the Department of Health centres around three strategic objectives.
• Better health and well-being for all: helping people stay healthy and well; empowering people to live independently; and tackling health inequalities.
• Better care for all: the best possible health and social care that offers safe and effective care, when and where people need it; and empowering people in their choices.
• Better value for all: delivering affordable, efficient and sustainable services; contributing to the wider economy and the nation.
Hamid Yunis, partner and head of healthcare at the London office of international law firm, McDermott Will & Emery, discusses the potential negative impact of Brexit and the UK leaving…
Among the assorted pharma CEOs and KOLs gathered at the recent Financial Times Pharmaceutical and Biotechnology Conference in London, debate raged on the pros and cons of a pure play strategy, focusing…
In an exclusive interview at the eyeforpharma Barcelona Summit 2016, Janssen EMEA’s Jane Griffiths speaks out about patient-centricity, sustainability and the dawning of a new world of healthcare. What’s been keeping you…
In an exclusive interview at the eyeforpharma Barcelona Summit 2016, GSK’s Danie Du Plessis speaks out about patient-centricity and the growing role of medical affairs in the pharma industry. In your…
Can you provide us with an overview of what the UK market represents for the greater Lonza group? Lonza Biologics is a contract manufacturing organisation employing approximately 650 people in…
Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have for the company? When…
As the head of Eisai’s European operations, how would you assess the relevance of the European market for Eisai’s global operations when compared to the US or emerging markets? Gary…
Following the acquisition of Arrow Generics by Watson in December 2009, what complementarities and synergies were generated from the transaction and where do you stand today with the integration? Since…
As a partner at Apposite since the company was created in 2006, what was the founding vision of the company and what do you consider have been its major milestones…
Apitope’s research and success is based on its High Speed Technology Platform that uses soluble peptides as vehicles to regulate immune responses in patients. What is the history behind this…
As the global economic roller coaster continues to unfold, governments the world over have desperately been scrambling to find the right policies that will effectively clamp on the brakes to…
Given the global trend of clinical research increasingly being outsourced to emerging markets, such as Asia and Latin America, where does this leave historical hubs of clinical research such as…
See our Cookie Privacy Policy Here